Literature DB >> 10752877

Focal lesions in the cirrhotic liver: high resolution ex vivo MRI with pathologic correlation.

G A Krinsky1, V S Lee, N D Theise.   

Abstract

Cirrhosis is a progressive, diffuse process of liver fibrosis that is characterized by architectural distortion and the development of a spectrum of nodules ranging from benign regenerative nodules to premalignant dysplastic nodules to overtly malignant hepatocellular carcinoma. The purpose of this essay is to demonstrate the ex vivo MR and pathology findings of these nodules as well as other masses that can be seen in the cirrhotic liver. The optimal conditions under which ex vivo imaging can be performed allow greater spatial resolution than that achieved with in vivo imaging, without artifacts that may degrade image quality. Clearly, contrast-enhanced MRI is essential for both the diagnosis and the characterization of focal lesions in the cirrhotic liver. However, the use of ex vivo imaging precludes the evaluation of these important in vivo pulse sequences.

Entities:  

Mesh:

Year:  2000        PMID: 10752877     DOI: 10.1097/00004728-200003000-00002

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  3 in total

1.  Assessment of liver volume variation to evaluate liver function.

Authors:  Cong Tong; Xinsen Xu; Chang Liu; Tianzheng Zhang; Kai Qu
Journal:  Front Med       Date:  2012-09-28       Impact factor: 4.592

2.  MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers.

Authors:  L Macarini; P Milillo; A Cascavilla; G Scalzo; L Stoppino; R Vinci; G Moretti; G Ettorre
Journal:  Radiol Med       Date:  2009-11-09       Impact factor: 3.469

3.  Assessment of hemodynamics in precancerous lesion of hepatocellular carcinoma: evaluation with MR perfusion.

Authors:  Sheng Guan; Wei-Dong Zhao; Kang-Rong Zhou; Wei-Jun Peng; Feng Tang; Jian Mao
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.